ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

317
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
22 Dec 2024 06:30

Last Week In Event SPACE: Seven & I, CPMC, UBTech Robotics, Macromill, 2024 Best-Of

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

Logo
526 Views
Share
20 Dec 2024 15:18

GAPack (468 HK): XJF Satisfies Pre-Cons. Management Should Back Terms

Bi/Hong will likely stick to their guns, and reject XJF's offer, and hope the deal fails. Minority shareholders should ignore that advice and tender.

Logo
719 Views
Share
19 Dec 2024 10:58

Henlius (2696 HK): This Should Trade Tighter. Get Involved

A 3.1% gross spread with expected payment around mid-Feb is okay. I'd pay up to HK$24.10/share for a 15% annualised spread. This is done. Get...

Logo
497 Views
Share
17 Dec 2024 00:51

Henlius (2696 HK): NDRC Approval Should Calm Nerves

Fosun Pharma has satisfied the precondition related to its Henlius’ HK$24.60 offer. The composite document will be despatched by 23 January. Key...

Logo
825 Views
Share
bullishESR Group
16 Dec 2024 01:34

Merger Arb Mondays (16 Dec) - ESR, CPMC, Fosun Tourism, Seven & I, Fuji Soft, NEC Networks

This week, the highest gross spreads are Arcadium Lithium (13.8%), Seven & I (11.6%), Insignia (10.8%), Henlius (10.8%), Get Nice (10.3%), ESR...

Logo
472 Views
Share
x